Compare GHM & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHM | APMD |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1994 | 2026 |
| Metric | GHM | APMD |
|---|---|---|
| Price | $87.90 | $26.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $73.33 | N/A |
| AVG Volume (30 Days) | 141.5K | ★ 359.1K |
| Earning Date | 06-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.90 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $245,293,000.00 | N/A |
| Revenue This Year | $14.54 | N/A |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | $265.09 | ★ N/A |
| Revenue Growth | ★ 16.86 | N/A |
| 52 Week Low | $48.47 | $20.02 |
| 52 Week High | $125.82 | $35.29 |
| Indicator | GHM | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 48.88 |
| Support Level | $75.91 | $24.88 |
| Resistance Level | $89.65 | $29.43 |
| Average True Range (ATR) | 4.20 | 2.61 |
| MACD | -0.53 | -0.24 |
| Stochastic Oscillator | 16.94 | 21.63 |
Graham Corp designs and manufactures mission-critical fluid, power, heat transfer, vacuum, and mixing technologies for the Defense, Energy & Process, and Space industries. In Defense, its equipment is used in nuclear and non-nuclear propulsion, power, fluid transfer, thermal management, and mixing systems. In Energy & Process industries, it supplies equipment for vacuum, heat transfer, mixing, and fluid transfer applications used in oil refining, chemical facilities, fertilizers, ethylene, methanol, energetics, food & beverage, medical, and alternative energy applications such as hydrogen and geothermal processes. In the Space industry, its equipment is used in propulsion, power, thermal management, mixing, and life support systems. It operates in the United States and other countries.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).